news

Specific batches of levothyroxine recalled as precautionary measure

7
SHARES

Due to a notification of the impurity, liothyronine, exceeding the specification limit, certain batches of levothyroxine 100micrograms/5ml oral solution are being recalled.

Batches of levothyroxine recalled as a precautionary measure

Wockhardt UK Ltd is recalling specific batches of levothyroxine 100micrograms/5ml oral solution from pharmacies and wholesalers as a precautionary measure due to notification of the impurity liothyronine exceeding the specification limit, the UK Medicines and Healthcare Products Regulatory Agency has announced in an alert. 

 

SECURE YOUR FREE SPOT

 


This webinar to explore rapid sterility testing methods that ensure fast, reliable product release, addressing critical challenges in timely delivery and safety.

Harnessing digital PCR for rapid sterility testing | 18 March 2026 | 3PM

What you’ll discover:

  • Rapid sterility testing methods that address the challenge of lengthy testing times, improving efficiency and ensuring timely product release
  • Insights into how digital PCR technology enhances testing accuracy and sensitivity, detecting contaminants quickly and reliably
  • Real-world case studies on rapid testing implementations in the field of cell and gene therapy

A Q&A session at the end of the webinar gives the audience a chance to ask questions, such as how to implement these technologies effectively.

Register now – it’s free

Liothyronine is a breakdown product that is present in levothyroxine formulations. Liothyronine, the synthetic form of the natural thyroid hormone tri-iodothyronine, can itself be used to treat an under-active thyroid but is generally reserved to treat more severe forms of the condition. This is because liothyronine has a faster onset of action and is also more potent than levothyroxine.

These differences in action mean there is a higher risk of adverse effects with increasing liothyronine content and is why the chemical is controlled within strict limits during levothyroxine preparations. This potency difference will result in different pharmacodynamic effects for patients.

Heathcare professionals are being advised to stop supplying the products immediately and quarantine all remaining stock and return it to the original suppliers using the suppliers’ approved processes.

For further information on the recalled levothyroxine products, including batch numbers, pack size and expiry dates, click the link here.

Share via
Share via